Document Detail

Therapeutic cancer vaccine fulfills the promise of immunotherapy in prostate cancer.
MedLine Citation:
PMID:  21174555     Owner:  NLM     Status:  PubMed-not-MEDLINE    
For many years, preclinical and clinical studies have attempted to harness the power of the immune system and focus it on malignant cells in an attempt to improve clinical outcomes for patients with cancer. This paper describes the landmark Phase III trial that led to the first US FDA approval of a therapeutic cancer vaccine. In a randomized trial of 512 patients, those treated with sipuleucel-T survived for 25.8 months compared with those treated with placebo, who survived 21.7 months (HR: 0.78; p = 0.03). There was, however, no change in time to progression, which may relate to the underlying mechanism of this new class of therapeutics.
Ravi A Madan; James L Gulley
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Intramural    
Journal Detail:
Title:  Immunotherapy     Volume:  3     ISSN:  1750-7448     ISO Abbreviation:  Immunotherapy     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2010-12-22     Completed Date:  2011-04-11     Revised Date:  2013-03-28    
Medline Journal Info:
Nlm Unique ID:  101485158     Medline TA:  Immunotherapy     Country:  England    
Other Details:
Languages:  eng     Pagination:  27-31     Citation Subset:  -    
Laboratory of Tumor Immunology & Biology, Center for Cancer Research, National Cancer Institute, 10 Center Drive, 8B09 MSC 1750, Bethesda, MD 20892, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Grant Support
Z01 BC010666-03/BC/NCI NIH HHS

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Defining the mechanisms of CD8 T-cell tumor tolerance.
Next Document:  Enhancing the specificity of T-cell cultures for adoptive immunotherapy of cancer.